Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 4/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16728466 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1POLBGABRR1L3MBTL1 | |
| SCHEMBL5417560 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1POLBGABRR1L3MBTL1 | |
| SCHEMBL23061770 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1POLBGABRR1L3MBTL1 | |
| SCHEMBL5420877 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1POLBGABRR1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL5415121 | 0.97 | SLC1A2 (0.41) | SLC1A2SLC1A1POLBGABRR1L3MBTL1 | |
| SCHEMBL3466144 | 0.97 | SLC1A2 (0.41) | SLC1A2SLC1A1POLBGABRR1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL5415118 | 0.97 | SLC1A2 (0.41) | SLC1A2SLC1A1POLBGABRR1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL5422436 | 0.97 | SLC1A2 (0.41) | SLC1A2SLC1A1POLBGABRR1L3MBTL1 | |
| SCHEMBL15057174 | 0.87 | POLB (0.55) | SLC1A2SLC1A1POLBGABRR1L3MBTL1 | |
| SCHEMBL8742210 | 0.87 | POLB (0.55) | SLC1A2SLC1A1POLBGABRR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110114349-B | Thiophene derivatives as antiviral agents | 埃尼奥制药公司 | 2022-03-15 | — | — | CN | claimed |
| US-10966944-B2 | [2.2.2] bicyclic derivatives and methods of use | ASE PHARMACEUTICALS LLC (US) | 2021-04-06 | — | — | US | claimed |
| US-10751307-B2 | [2.2.2] bicyclic derivatives and methods of use | ASE PHARMACEUTICALS LLC (US) | 2020-08-25 | — | — | US | claimed |
| EP-2396002-B1 | (2.2.2) BICYCLIC DERIVATIVES AND METHODS OF USE | ASE PHARMACEUTICALS LLC (US) | 2020-07-29 | — | — | EP | claimed |
| US-20200215008-A1 | [2.2.2] BICYCLIC DERIVATIVES AND METHODS OF USE | ASE PHARMACEUTICALS LLC (US) | 2020-07-09 | — | — | US | claimed |
| US-20180200211-A1 | [2.2.2] BICYCLIC DERIVATIVES AND METHODS OF USE | ASE PHARMACEUTICALS LLC (US) | 2018-07-19 | — | — | US | claimed |
| US-9943493-B2 | [2.2.2] bicyclic derivatives and methods of use | ASE PHARMACEUTICALS, LLC (US) | 2018-04-17 | — | — | US | claimed |
| CN-106309418-A | [2.2.2] bicyclic derivatives and methods of use | 艾思益制药有限责任公司 | 2017-01-11 | — | — | CN | claimed |
| US-20170000750-A1 | [2.2.2] BICYCLIC DERIVATIVES AND METHODS OF USE | ASE PHARMACEUTICALS, LLC | 2017-01-05 | — | — | US | claimed |
| EP-0790974-B1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER AG (US) | 2002-08-14 | — | — | EP | claimed |
| EP-4716531-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | Board of Regents, The University of Texas System (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4709708-A1 | NOVEL CARBOXAMIDE DERIVATIVES | ANGELINI PHARMA S.P.A. (IT) | 2026-03-18 | — | — | EP | disclosed |
| US-20250257041-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-08-14 | — | — | US | disclosed |
| WO-2025106780-A1 | RXFP1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4526291-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | The Board of Regents of the University of Texas System (US) | 2025-03-26 | — | — | EP | disclosed |
| US-6166082-A | Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors | BAYER CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0790974-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | Bayer Corporation (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0626942-A1 | BICYCLO 2.2.2.]OCTANE DERIVATIVES AS CHOLESTOCYSTOKININ INHIBITORS. | BLACK JAMES FOUNDATION (GB) | 1994-12-07 | — | — | EP | disclosed |
| WO-1993016982-A1 | BICYCLO[2.2.2.]OCTANE DERIVATIVES AS CHOLESTOCYSTOKININ INHIBITORS | JAMES BLACK FOUNDATION LIMITED (GB) | 1993-09-02 | — | — | WO | disclosed |
| US-4026851-A | ETHYLENE-ACRYLATE, ETHYLENE-METHACRYLATE-ACRYLATE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257041-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | DDIT3, ATF4, EIF2AK3 | SLC1A2 4581/4885SLC1A1 4395/4885POLB 2089/4885 |
| US-20200215008-A1 | [2.2.2] BICYCLIC DERIVATIVES AND METHODS OF USE | OAT, GOT2, FABP1 | SLC1A2 9/4885SLC1A1 86/4885POLB 2472/4885 |
| US-10751307-B2 | [2.2.2] bicyclic derivatives and methods of use | OAT, GABRA2, GOT2 | SLC1A2 15/4885SLC1A1 97/4885POLB 1987/4885 |
| US-10966944-B2 | [2.2.2] bicyclic derivatives and methods of use | OAT, GOT2, FABP1 | SLC1A2 9/4885SLC1A1 86/4885POLB 2472/4885 |
| US-20170000750-A1 | [2.2.2] BICYCLIC DERIVATIVES AND METHODS OF USE | OAT, GABRA2, GOT2 | SLC1A2 15/4885SLC1A1 97/4885POLB 1987/4885 |
| US-20180200211-A1 | [2.2.2] BICYCLIC DERIVATIVES AND METHODS OF USE | OAT, GABRA2, GOT2 | SLC1A2 15/4885SLC1A1 97/4885POLB 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.